Association between Interferon-Lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 Variant Polymorphisms with the Course and Outcome of SARS-CoV-2 Patients

Sara H. A. Agwa 1,*; Marwa Mostafa Kamel 2; Hesham Elghazaly 3*; Aya M. Abd Elsamee 4; Hala Hafez 5; Samia Abdo Girgis 5; Hoda Ezz Elarab 5; Fatma S. E. Ebeid 6; Safa Matbouly Sayed 6; Lina Sherif 7; and Marwa Matboli 2,*

1 Molecular Genomics Unit, Clinical Pathology Department, Medical Ain Shams Research Institute (MASRI), School of Medicine, Ain Shams University, Cairo 11566, Egypt
2 Medicinal Biochemistry and Molecular Biology Department, School of Medicine, Ain Shams University, Cairo 11566, Egypt; Marwa.kamel88@med.asu.edu.eg
3 Oncology Department, Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo 11566, Egypt; heshamelghazaly@hotmail.com
4 Molecular Genomics Unit, Medical Ain Shams Research Institute (MASRI), Ain Shams University, Cairo 11566, Egypt; aya.anu2025@yahoo.com
5 Infection Control Unit, Clinical Pathology Department, Ain Shams University Hospitals, Cairo 11566, Egypt; Dr.hmhafez@gmail.com (H.H.); Drsamia.girgis@med.asu.edu.e (S.A.G.); Hodaezz55@yahoo.com (H.E.E.)
6 Pediatric Department, School of Medicine, Ain Shams University Hospitals, Cairo 11566, Egypt; fatmaebeid@med.asu.edu.e (F.S.E.E.); safamatboly@yahoo.com (S.M.S.)
7 Department of Clinical Pharmacy, Faculty of Pharmacy, Misr International University, Cairo 11566, Egypt; Lina1405218@miuegypt.edu.eg

* Correspondence: sarakariem@gmail.com (S.H.A.A.); DrMarwa.Matboly@med.asu.edu.e (M.M.)

Abstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provides a critical host-immunological challenge. Aim: We explore the effect of host-genetic variation in interferon-lambda-3 rs12979860, Tolloid Like–1 (TLL1) rs17047200 and Discoidin domain receptor 1 (DDR1) rs4618569 on host response to viral infections and disease severity that may probe the mechanistic approach of allelic variation in virus-induced inflammatory responses. Methods: 141 COVID-19 positive patients and 100 healthy controls were tested for interferon-lambda-3 rs12979860, TLL1 rs17047200 and DDR1 rs4618569 polymorphism by TaqMan probe-based genotyping. Different genotypes were assessed regarding the COVID-19 severity and prognosis. Results: There were statistically significant differences between the studied cases and control group with regard to the presence of comorbidities, total leukocytic count, lymphocytic count, CRP, serum LDH, ferritin and D-dimer (p < 0.01). The CC genotype of rs12979860 cytokine, the AA genotype of TLL1 rs17047200 and the AA genotype of the rs4618569 variant of DDR1 showed a higher incidence of COVID-19 compared to the others. There were significant differences between the rs4618569 variant of DDR and the outcome of the disease, with the highest mortality in AG genotype 29 (60.4 %) in comparison to 16 (33.3 %) and 3 (6.2 %) in the AA and GG genotypes, respectively (p = 0.007*), suggesting that the A allele is associated with a poor outcome in the disease. Conclusion: Among people who carry C and A alleles of SNPs IFN-λ rs12979860 and TLL1 rs17047200, respectively, the AG genotype of the DDR1 rs4618569 variant is correlated with a COVID-19 poor outcome. In those patients, the use of anti-IFN-λ 3, TLL1 and DDR1 therapy may be promising for personalized translational clinical practice.

Keywords: severe acute respiratory syndrome coronavirus 2; coronavirus; immune response; innate immunity; polymorphisms; single nucleotide; cytokine
1. Introduction

Most cases with severe acute respiratory syndrome coronavirus 2 (The SARS-CoV-2) infection demonstrate mild symptoms or are asymptomatic, but some cases may develop complications such as interstitial pneumonia and acute respiratory distress syndrome (ARDS), as seen in patients with advanced age and associated morbidities [1].

The relation between SNPs and the immune response is called “immunogenetic profiling” [2]. Genetic polymorphism plays an important role in cytokine function, which is crucial in the host inflammatory response [3]. Cytokine polymorphisms affect gene transcription and expression, and subsequently the amount of cytokine secreted according to the genotype of the cytokine [4,5]. The cytokine polymorphisms could be associated with rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus [6].

Knowing that cytokines are crucial regulators of the individual response to infections [7], it is becoming clear that the immune system has an evident role in the cytokine storm as dangerous events in the disease known as ARDS [8,9]. Understanding the variables between subjects that could lead to this outcome is the cornerstone for identifying targeted therapeutic strategies [10].

rs12979860 is a single nucleotide polymorphism (SNP) previously known as interferon-lambda-3 (IFN-lambda-3). Retrieved from literature, it was found to be connected with the host viral immune defense [11–13]. The rs12979860 SNP is found upstream of the IFN-λ 3 gene in the promoter sequence. It produces IL28A (IFN-λ 2), IL28B (IFN-λ 3) and IL29 (IFN-λ 1), members of cytokines in the IFN-λ family [14]. They share in the regulation of the host immune response in viral infections [15].

TLL1 rs17047200 SNP may produce catalytically highly active short isoform (TLL1 isoform 2) [16]. Of note, we evaluated a SNP of Tolloid Like-1 (TLL-1) as a complementary activating protease and also as potentially able to stimulate the spike protein of SARS-CoV-2 [17].

Discoidin domain receptor 1 (DDR1) is a tyrosine kinase receptor that plays a role in b1 integrins signaling [18]. DDR1 activation by collagen affects human leukocytes' functions as cell differentiation and cytokine production [19]. DDR1 modulates E-cadherin and integrin CCN3-dependent cell adhesion to collagen type IV [20]. We focused on cytokine polymorphisms at rs12979860 and rs17047200 loci, the allele frequencies reported in previous literatures and DDR1 gene polymorphism in COVID-19 positive patients to explore their relation to coronavirus infection severity and mortality.

The goal of the study is to assess the association between rs12979860, TLL1 rs17047200 and DDR1 rs4618569 polymorphism and coronavirus disease of 2019 (COVID-19) outcomes, because the earlier prediction of the host genotype and the severity of the disease will alleviate the economic burden or mortality rate of COVID-19.

2. Materials and Methods

2.1. Study Design and Demographic Data

This is a case-control study that was performed on blood samples from patients that were admitted to the pediatric, ENT, chest and internal medicine department at Ain Shams university hospitals.

We recruited 141 COVID-19 positive patients, including 23 (16%) from pediatric patients, 87 (61.7%) from the chest department and 31 (22%) from the geriatric department, and 100 healthy controls coming for a routine check-up visit during the period from May 2020 to March 2021. COVID-19 diagnosis depends on the characteristic clinical and computed tomography (CT) scan of the chest and confirmed by the positive qRT-PCR for COVID-19 in a nasopharyngeal swab. COVID-19 was classified as 82 mild cases (58%), 11 severe cases (7.8%) and 48 critical cases (34%). Classification of COVID-19 patients' severity was according to the Egyptian MOH protocol, version 1.4 [21] into mild, moderate, severe or critical groups. Patients with mild cases are either asymptomatic or display leucopenia or lymphopenia and without pneumonia in a CT image. Severe cases had a respiratory rate > 30 breaths/min or a PaO₂/FiO₂ ratio < 300, SpO₂ ≤ 92% in room air or
a CT showing higher than 50% progressive lesion within 1–2 days. Critical cases had a PaO\textsubscript{2}/FiO\textsubscript{2} ratio < 300 despite O2 therapy or SpO\textsubscript{2} ≤ 92% in room air or a respiratory rate >30 breaths/min.

A complete history was taken from each patient focusing on (i) history of comorbidities as diabetes, hypertension, asthma or combined; (ii) severity of the disease (whether ventilated or not). A complete blood count—D-dimer, serum ferritin, C-reactive protein (CRP), lactate dehydrogenase (LDH)—was performed on all participants at the time of diagnosis of SARS-CoV-2 infection.

Patient nasopharyngeal swabs were collected for viral RNA isolation followed by purification using the QIAamp Viral RNA Mini kit (Cat no. 52906; Qiagen, Tokyo, Japan) based on the manufacturer’s guidelines.

2.2. SNP Genotyping

2.2.1. Extraction of Total RNA from Whole Blood Samples

SNPs genotyping was carried out on the extracted RNA. We used the QIAamp RNA Blood Mini kit (Qiagen, Valencia, CA, USA) to purify total RNA from the whole blood samples based on the manufacturer’s guidelines. We assessed the RNA concentration and integrity using the Qubit 3.0 fluorometer (Invitrogen, serial no. 2321609092). Then, the extracted total RNA was reverse-transcribed into cDNA by the high-capacity cDNA Reverse Transcription kit (A. B., Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol on the Thermo Hybaid polymerase chain reaction PCR express (Thermo Scientific, Missouri City, TX, USA).

2.2.2. Genotyping Methodology

The SNP assay coded by C\textsubscript{33773674_10} (rs17047200) Lot: p180806-009 C03, C\textsubscript{7820464_10} (rs12979860) Lot: p180115-001 E12 and C\textsubscript{2437004_20} (rs4618569) Lot: P200101-000 B06 Applied Biosystems predesigned TaqMan SNP genotyping Assays (cat.no: 4351379, Thermo Scientific, A.B., Missouri City, TX, USA) and TaqMan universal master mix II (PN: 4428173, Thermo Scientific, A.B., Missouri City, TX, USA) were genotyped using the TaqMan genotyping allelic discrimination method. All PCR reactions were done in 50 \(\mu\)L reaction volumes: 25 \(\mu\)L TaqMan Universal Master Mix II, 2.5 \(\mu\)L TaqMan Assay and cDNA+RNase-free water 22.5 \(\mu\)L to reach a total final volume of 50 \(\mu\)L per reaction. PCR reactions were performed on the Applied Biosystems Tm 7500 Real-Time PCR system (Foster City, CA, USA). The following thermocycler conditions were adopted: 95°C for 10 min hold and denaturation at 95°C for 15 s, then annealing and extension at 60°C for 1 min in 40 cycles.

Endogenous control genes were used to normalize the raw data of the samples followed by comparing the results to a reference sample. In this study, MIQE guidelines were followed to avoid any experimental error during extraction and RNA processing.

2.2.3. Statistical Analysis

Statistical social packages of SPSS software version 20 were used. Qualitative data were described using the number and percent. Quantitative data were analyzed using the median for non-parametric data and the mean ± SD for parametric data. The statistical significance was considered at the (0.05) level. Qualitative data were analyzed using the Chi-Square test. The statistical relevance of the relationship between genotypes and risk of COVID-19 was expressed by an odds ratio (OR) with its 95% confidence interval (95% CI). The Hardy–Weinberg equilibrium was applied to compare the genotype distribution among the studied groups. Spearman Rank Correlation tests were assessed between different genotypes.
3. Results
3.1. Patient Sociodemographic and Clinicopathological Features

No statistically significant differences were found between COVID-19 positive patients and controls regarding age or sex with \( p = 0.252 \) and 0.201, respectively. The mean age of the patients was 37.42 ± 20.51, and females represent 43.2% of cases. Comorbidities (including diabetes mellitus, hypertension, chronic pulmonary disease, renal disease and cardiac disease) were found in 57.4% of cases and 18% of controls. There was a significant difference between the COVID-19 patients and the healthy control group with regard to the presence of comorbidities, total leucocytic count, lymphocytic count, CRP, serum LDH, ferritin and D-dimer (\( p < 0.01 \)) (Table 1).

Table 1. Clinicopathological and laboratory data between the investigated groups.

| Test of Significance |
|----------------------|
| Sex                  |
| Male 137 (56.8%)     |
| Female 104 (43.2%)   |
| Comorbidities        |
| +ve 99 (41.1%)       |
| –ve 142 (58.9%)      |
| Comorbidities        |
| +ve 99 (41.1%)       |
| –ve 142 (58.9%)      |
| Severity             |
| Mild 82 (58.2%)      |
| Severe 11 (7.8%)     |
| Critical 48 (34%)    |
| Ventilation          |
| +ve 54 (38.3%)       |
| –ve 87 (61.7%)       |
| Outcome              |
| Recovery 63 (44.7%)  |
| Recurrence 30 (21.3%)|
| Death 48 (34%)       |
| Age/years            |
| Median 38            |
| Mean 37.42           |
| ±SD 20.51            |
| Median 33            |
| Mean 34.27           |
| ±SD 21.62            |
| Total leucocytic count (TLC) (thousands/cmm) |
| 9.3 17.41 29.54      |
| 7 9.36 11.59        |
| Lymphocytes (×10^9/L) |
| 1.06 1.16 0.52      |
| 3.3 3.24 0.86       |
| Hemoglobin (g/dL)    |
| 12.8 12.09 2.07     |
| 12.3 12.21 2.46     |
| Platelets (PLTs) (thousands/cmm) |
| 261 260.31 77.89    |
| 222 244.52 99.78    |
| C-reactive protein (mg/L) |
| 39.5 70.60 78.83    |
| 0.3 0.88 1.34       |
| Serum Lactate dehydrogenase (LDH) (U/L) |
| 271 376.32 251.20   |
| 147 166.52 50.39    |
| Ferritin (ng/mL)     |
| 165 361.12 418.87   |
| 31.5 42.27 31.97    |
| D-dimer (mg/L)       |
| 5 132.05 430.95     |
| 0.10 0.12 0.10      |

\( t \): Student t-test; \( \chi^2 \): Chi-Square test; TLC: Total Leucocytic Count; Comorbidities include diabetes mellitus, hypertension, asthma and combined comorbidities; * statistically significant.
3.2. Genotypes Characteristics

TaqMan-based genotyping revealed the following: With regard to the interferon-lambda-3 rs12979860, 19 (13.5%) patients were TT, 59 (41.8%) were TC and 63 (44.7%) were CC. With regard to the control group, 12 (12%) of them were TT, 44 (44%) were TC and 44 (44%) were CC using \( \chi^2 \): Chi-Square test (Table 2). Remarkably, it seems that the CC genotype of the rs12979860 cytokine showed a higher incidence of COVID-19 compared to the healthy control group (\( p = 0.011 \)).

With regard to TLL1 rs17047200, 94 (66.7%) patients were AA, 37 (26.2%) were AT and 10 (7.1%) were TT. The healthy control group was represented as 66 (66%) AA, 26 (26%) AT and 8 (8%) TT (Table 2). From these data, it appears that the AA genotype of the TLL1 rs17047200 cytokine showed a higher incidence of the disease in comparison to the control group, with \( p = 0.012 \).

With regard to DDR1 rs4618569, 66 (46.8%) patients were AA, 56 (39.7%) were AG and 19 (13.5%) were GG. With regard to the control group, 62 (62%) of them were AA, 24 (24%) were AG and 14 (14%) were GG (Table 2). From these data, it appears that the AA genotype of the rs4618569 variant of the DDR1 gene had a higher incidence of COVID-19 compared to the healthy control group (\( p = 0.026 \)) (Table 2).

Table 2. Genotype frequencies between the studied groups.

| Genotypes      | Cases (141) n (%) | Control (100) n (%) | Test of Significance \( \chi^2 \) | Odd’s Ratio (95% CI) |
|----------------|-------------------|---------------------|----------------------------------|----------------------|
| IFN-\( \lambda \) rs12979860 Genotypes | | | | |
| TT n = 31 (13%) | 19 (13.5%) | 12 (12%) | 0.242 (0.702) | 0.876 (0.404–1.897) |
| TC n = 103 (43%) | 59 (41.8%) | 44 (44%) | 0.111 (0.792) | 1.092 (0.651–1.832) |
| CC n = 107 (44%) | 63 (44.7%) | 44 (44%) | 0.011 * (1.00) | 0.973 (0.581–1.630) |
| Allele | | | | |
| T n = 165 (34%) | 97 (34%) | 68 (34%) | | |
| C n = 317 (66%) | 185 (66%) | 132 (66%) | | |
| Hardy–Weinberg Equilibrium | 0.45 | 0.83 | | |
| TLL1 rs17047200 Genotypes | | | | |
| AA n = 160 (66%) | 94 (66.7%) | 66 (66%) | 0.012 * (1.00) | 0.971 (0.564–1.669) |
| AT n = 63 (26%) | 37 (26.2%) | 26 (26%) | 0.002 * (1.00) | 0.988 (0.551–1.770) |
| TT n = 18 (7%) | 10 (7.1%) | 8 (8%) | 0.070 (0.808) | 1.139 (0.433–2.996) |
| Allele | | | | |
| A n = 383 (79%) | 225 (80%) | 158 (79%) | | |
| T n = 99 (21%) | 57 (20%) | 42 (21%) | | |
| Hardy–Weinberg Equilibrium | 0.034 | 0.035 | | |

...
We applied the Hardy–Weinberg equation to determine whether the frequency of each genotype obtained agrees with expected values, as calculated from allele frequencies. Its value was 0.45 for cases and 0.83 for controls with regard to the first SNP, and 0.034 for cases and 0.035 for controls with regard to the TLL1 rs17047200 SNP and 0.034 for cases and 0.035 for controls with regard to the DDR1 rs4618569 SNP. Haplotype analysis was done without a global haplotype association, \( p \)-value = 0.56 (Table 2).

Of note, there were no statistically significant differences between the different genotypes regarding the demographic and laboratory features. With regard to the IFN-\( \lambda \) rs12979860 SNP, the TC genotype was associated with the presence of comorbidities and an increased mortality rate compared to the other genotypes. With regard to the TLL1 rs17047200 SNP, the AA genotype was associated with an increased risk for comorbidities and an increased risk for ventilation, and a decreased total leucocytic count was associated with disease severity with increased mortality rate; a significant difference was found between the different genotypes of SNP 2 (rs17047200) and CRP and the severity of the disease (\( p = 0.01, p = 0.02 \), respectively). With regard to the DDR1 rs4618569 SNP, the AG genotype was associated with an increased risk of comorbidities and an increased risk of ventilation, high CRP, Ferritin, D-dimer, and disease severity with increased mortality rate (Supplementary Table S1).

Interestingly, regarding the IFN-\( \lambda \) rs12979860 SNP (rs12979860), 27 (45.8%) cases of the TC genotype were classified as a severe disease compared to 22 (34.9%) and 10 (52.6%) cases in the CC and TT genotype, respectively, with \( p = 0.283 \). With regard to the TLL1 rs17047200 SNP, in 36 (38.3%) cases of the AA genotype, the disease was severe in comparison to 16 (43.2%) cases in the AT genotype and 7 (70%) cases in the TT genotype, with \( p = 0.152 \). With regard to the DDR1 rs4618569 SNP, in 34 (60.7%) cases of the AG genotype, the disease was severe in comparison to 20 (30.3%) cases in the AA genotype and 5 (26.3%) cases in the GG genotype, with \( p < 0.01^* \) (Supplementary Table S1).

3.3. Genotypes and Outcome of the Disease

There were significant differences between the DDR1 rs4618569 SNP and the outcome of the disease, with the highest mortality in the AG genotype: 29 (60.4%) in comparison to 16 (33.3%) and 3 (6.2%) in the AA and GG genotypes, respectively (\( p = 0.007^* \)), suggesting that the A allele is associated with a poor outcome in the disease. With regard to the IFN-\( \lambda \) rs12979860 SNP, the poor outcome is associated with the C allele and with the A allele in the TLL1 rs17047200 SNP (Table 3).

---

### Table 2. Cont.

| Genotypes            | Cases (141) n (%) | Control (100) n (%) | Test of Significance \( \chi^2 \) | Odd's Ratio (95% CI) |
|----------------------|-------------------|---------------------|---------------------------------|---------------------|
| **DDR1 rs4618569 Genotypes** |                   |                     |                                 |                     |
| AA \( n = 128 \) (80%) | 66 (46.8%)        | 62 (62%)            | 5.422 (0.026)                   | 1.854 (1.100–3.125) |
| AG \( n = 80 \) (33%) | 56 (39.7%)        | 24 (24%)            | 6.517 (0.012)                   | 0.479 (0.271–0.847) |
| GG \( n = 33 \) (14%) | 19 (13.5%)        | 14 (14%)            | 0.014 * (1.00)                  | 1.045 (0.497–2.198) |
| **Allele**           |                   |                     |                                 |                     |
| A 336 (70%)          | 188 (67%)         | 148 (74%)           |                                 |                     |
| G 146 (30%)          | 94 (33%)          | 52 (26%)            |                                 |                     |
| **Hardy–Weinberg Equilibrium** | 0.25              | 0.00039 *           |                                 |                     |

\( \chi^2 \): Chi-Square test; * statistically significant.
Table 3. Risk factors of death among studied cases (COVID-19).

|                      | Recovery \( n = 63 \) | Recurrence \( n = 30 \) | Death \( n = 48 \) | Test of Significance |
|----------------------|------------------------|--------------------------|-------------------|----------------------|
| **Age/years**        | 51.08                  | 74.33                    | 95.06             | \( \chi^2 = 31.846 \) <br> \( p = 0.000 \ * \) |
| **Sex**              |                        |                          |                   |                      |
| Male 85 (60.3%)      | 42 (66.7%)             | 17 (56.7%)               | 26 (54.2%)        | \( X_2 = 1.986 \) <br> \( p = 0.370 \) |
| Female 56 (39.7%)    | 21 (33.3%)             | 13 (43.3%)               | 22 (45.8%)        |                      |
| **Comorbidities**    |                        |                          |                   |                      |
| +ve 81 (57.4%)       | 26 (41.3%)             | 18 (60%)                 | 37 (77.1%)        | \( X_2 = 14.396 \) <br> \( p = 0.001 \ * \) |
| −ve 60 (42.6%)       | 37 (58.7%)             | 12 (40%)                 | 11 (22.8%)        |                      |
| **Ventilation**      |                        |                          |                   |                      |
| +ve 32 (22.7%)       | 2 (3.2%)               | 6 (20%)                  | 46 (95.8%)        | \( X_2 = 104.381 \) <br> \( p = 0.000 \ * \) |
| −ve 109 (77.3%)      | 61 (96.8%)             | 24 (80%)                 | 2 (4.2%)          |                      |
| **Severity**         |                        |                          |                   |                      |
| Mild \( n = 82 \)    | 60 (95.2%)             | 22 (73.3%)               | 0 (0%)            | \( X_2 = 105.151 \) <br> \( p = 0.000 \ * \) |
| Severe \( n = 11 \)  | 3 (27.2%)              | 8 (72.7%)                | 0 (0%)            |                      |
| Critical \( n = 48 \)| 0 (0%)                 | 0 (0%)                   | 48 (100%)         |                      |
| **Haemoglobin (gm/dl)** | 69.64                | 104.10                   | 52.09             | \( \chi^2 = 30.226 \) <br> \( p = 0.000 \ * \) |
| **TLC (thousands/cmm)** | 62.85                | 63.42                    | 86.44             | \( \chi^2 = 10.441 \) <br> \( p = 0.005 \ * \) |
| **PLTs (thousands/cmm)** | 71.06                | 73.98                    | 69.06             | \( \chi^2 = 0.269 \) <br> \( p = 0.874 \) |
| **Lymphocytes (x10^9/L)** | 79.40                | 88.22                    | 49.22             | \( \chi^2 = 21.811 \) <br> \( p = 0.000 \ * \) |
| **Ferritin (ng/mL)** | 62.94                  | 64.42                    | 85.70             | \( \chi^2 = 9.472 \) <br> \( p = 0.009 \ * \) |
| **C-reactive protein (mg/L)** | 63.90                | 70.47                    | 80.66             | \( \chi^2 = 4.604 \) <br> \( p = 0.100 \) |
| **Serum LDH (U/L)**  | 71.68                  | 91.0                     | 57.60             | \( \chi^2 = 12.410 \) <br> \( p = 0.002 \ * \) |
| **D-dimer(mg/L)**    | 48.44                  | 69.42                    | 101.60            | \( \chi^2 = 46.883 \) <br> \( p = 0.000 \ * \) |
| **SNP 1 (rs12979860)** |                      |                          |                   |                      |
| TT 19 (13.5%)        | 5 (7.9%)               | 6 (20%)                  | 8 (16.7%)         | \( X_2 = 5.590 \) <br> \( p = 0.232 \) |
| TC 59 (41.8%)        | 27 (42.9%)             | 9 (30%)                  | 23 (47.9%)        |                      |
| CC 63 (44.7%)        | 31 (49.2%)             | 15 (50%)                 | 17 (35.4%)        |                      |
| **SNP 2 (rs17047200)** |                      |                          |                   |                      |
| AA 94 (66.7%)        | 47 (74.6%)             | 18 (60%)                 | 29 (60.4%)        | \( X_2 = 3.801 \) <br> \( p = 0.434 \) |
| AT 37 (26.2%)        | 13 (20.6%)             | 10 (33.3%)               | 14 (29.2%)        |                      |
| TT 10 (7.1%)         | 3 (4.8%)               | 2 (6.7%)                 | 5 (10.4%)         |                      |
| **SNP 3 (rs4618569)** |                      |                          |                   |                      |
| AA 66 (46.8)         | 33 (52.4%)             | 17 (56.7%)               | 16 (33.3%)        | \( X_2 = 14.193 \) <br> \( p = 0.007 \ * \) |
| AG 56 (39.7)         | 20 (31.7%)             | 7 (23.3%)                | 29 (60.4%)        |                      |
| GG 19 (13.5)         | 10 (15.9%)             | 6 (20%)                  | 3 (6.2%)          |                      |
4. Discussion

The COVID-19 crisis represents a worldwide health problem. By now, the global number of confirmed cases of COVID-19 reached 108.2 million cases with a mortality of 2.3 million cases. In Egypt, they reached 177,543 confirmed cases and 10,298 deaths [22]. Developing countries face a critical financial problem with their limited resources that highlights the urgent need for the identification of high-risk patients who develop complications to receive timely and effective therapeutic regimens [23]. A study by Ellinghaus et al. has tested for association between >8 million single nucleotide polymorphisms (SNPs) and the development of respiratory failure in COVID-19 patients [24]. Therefore, understanding crucial players in the cytokine storm-related mortality in COVID-19 is very important [25]. The work aimed to study the association of rs12979860, rs17047200 cytokines polymorphism and DDR1 gene variant rs4618569 with the progression and outcome in SARS-CoV-2 patients.

TaqMan based genotyping revealed that the frequency of the IFN-λ 3 SNP (rs12979860) showed that the CC genotype is more expressed in COVID-19 patients versus healthy controls \( (p = 0.011) \). Nineteen (13.5%) patients were TT, 59 (41.8%) were TC and 63 (44.7%) were CC versus 12 (12%), 44 (44%) and 44 (44%) in the healthy control group, respectively. These data suggest that persons who had the C allele (TC and CC) are at a higher risk to develop COVID-19. While the AA genotype of the TLL1 rs17047200 had higher expression in patients versus healthy controls, with \( p = 0.012 \). Ninety-four (66.7%) patients were AA, 37 (26.2%) were AT and 10 (7.1%) were TT versus 66 (66%), 26 (26%) and 8 (8%) in the control group, respectively. These results demonstrate that the persons carrying the A allele (AA and AT) are at higher risk of the disease. Concerning the AA genotype of the DDR1 rs4618569 variant, it is more likely to be found in COVID-19 patients versus healthy controls, with \( p = 5.422 \). Sixty-six (46.8%) patients were AA, 56 (39.7%) were AG and 19 (13.5%) were GG versus 62 (62%), 24 (24%) and 14 (14%) in the healthy control group, respectively. These results show that persons with the A allele, either AA or AG, are more susceptible to COVID-19.

In this COVID-19 global pandemic, we aim to identify host genomic factors that increase susceptibility and the complications of such a viral infection, and to translate these results in a timely manner to enhance patient care [26].

In our study, all patients showed higher levels of TLC, CRP, D-dimer, serum ferritin, LDH and lymphopenia, in agreement with Zhu et al. who found higher levels of these parameters in patients with COVID-19 infection [27].

Upon comparison of COVID-19 infection with different genotypes with regard to the disease severity and prognosis: The TC genotype of the IFN-λ 3 SNP (rs12979860), the AA genotype of TLL1 rs17047200 and the AG genotype of DDR1 rs4618569 variant are associated with more severe symptoms and lower favorable outcomes compared to the other genotypes. In the TC and CC genotypes of the IFN-λ 3 SNP (rs12979860), the disease was severe in 27 (45.8%) and 22 (34.9%) cases, respectively, in comparison to 10 (52.6%) cases in the TT genotype, \( p = 0.283 \). Mechanical ventilation was used in 24 cases of the TC genotype and 21 cases of the CC genotype compared to 9 cases in the TT genotype. In the AA genotype of TLL1 rs17047200, COVID-19 was severe in 36 (38.3%) cases compared to 16 (43.2%) cases in the TA genotype and 7 (70%) cases in the TT genotype, with \( p = 0.152 \). Mechanical ventilation was required in 31 cases of the AA genotype compared to 16 cases in the TA genotype and 7 cases in the TT genotype \( (p = 0.056) \).

In the AG genotype of the DDR1 rs4618569 variant, the disease was severe in 34 (60.7%) cases compared to 20 (30.3%) cases in the AA genotype and 5 (26.3%) cases in the GG genotype \( (p = 0.001) \). Mechanical ventilation was required in 32 cases of the AG genotype in comparison to 17 cases in the AA genotype and 5 cases in the GG genotype \( (p = 0.001) \). These data revealed that the C allele of the IFN-λ 3 SNP (rs12979860), the A allele of TLL1 rs17047200 and the A allele of the DDR1 rs4618569 variant are associated with more aggressive disease, and this may be correlated to changes in the product’s level of these loci in blood.
The rs12979860 SNP encodes the IFN-λ family of cytokines [28], which shared in the regulation of the host immune response against viral infections [29]. Many associations have been found between interferon lambda 3 rs12979860 polymorphism and various clinical outcomes as a control of the hepatitis C virus infection [30], myeloproliferative neoplasms, dengue virus in children and systemic lupus erythematosus [31].

In a GWAS, a research group declared the association between the TLL1 rs17047200 SNP and hepatocellular carcinoma pathogenesis and found elevated TLL1/TLL1 mRNA in animal models of liver injury and human liver tissues with fibrosis, in comparison with controls [32]. A previous study highlighted the association between rs4618569 of the DDR1 and vitiligo development [33]; the DDR1 gene seems to be an important player in immune responses, which depend on the effective migration of activated leukocytes into infectious or inflammatory tissue sites [34].

Of interest, regarding the prognosis and survival of COVID-19, the TC, AA and AG genotypes of the SNPs IFN-λ 3 SNP rs12979860, TLL1 rs17047200 and DDR1 rs4618569 variant, respectively, showed poor prognosis, where 23, 29 and 29 cases died, respectively, in comparison to lower deaths in the other genotypes. Our data showed an increased risk of death from COVID-19 in patients with advanced age, in agreement with Wang et al. who found that elderly males showed poor prognosis and an increased risk of COVID-19 severity [35], which could be explained by a decline in the immune function with aging and a decrease in the production of CD3+ T cells, and B lymphocytes, along with elevated regulatory T cells [36,37]. Another study confirmed that the poor outcome in elderly patients with SARS-CoV-2 was due to immunosenescence [38].

We suggest larger multicenter studies to explore the validity of these polymorphisms in COVID-19 patients. The study may be limited by the patients and by being a single-center study.

5. Conclusions

The C and A alleles of SNPs IFN-λ rs12979860, TLL1 rs17047200 correlate with the severity of COVID-19, where the AG genotype of the DDR1 rs4618569 variant are associated with severe COVID-19 cases and poor outcomes. These data suggest that innate immunity is closely linked with the outcome of SARS-CoV-2 infection.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/genes12060830/s1, Table S1: title Demographic and laboratory characters of Covid-19 cases according to genotype distribution, Table S2: Correlation between the frequencies of polymorphisms, severity and mortality rates of COVID-19 cases (Spearman’s rho).

Author Contributions: S.H.A.A. participated in funding acquisition and resources, supervision and original drafting—reviewing and editing. M.M.K. shared in data curation, methodology, validation, original drafting, methodology and investigation. H.E., A.M.A.E., H.H., S.A.G., H.E.E., F.S.E.E., S.M.S. and L.S. shared in data acquisition and formal analysis, validation and reviewing. M.M. shared in conceptualization, methodology, supervision and reviewing and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by Ain Shams University, School of Medicine, 2020–1.

Institutional Review Board Statement: The study was done based on the guidelines of the Declaration of Helsinki, and received the approval from the Research Ethics Committee, Faculty of Medicine, Ain Shams University, Egypt, dated 13/5/2020, FWA 00001684.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented are available on request by the corresponding authors.

Conflicts of Interest: All the authors have no conflict of interest to disclose.
References

1. Crayne, C.B.; Albeituni, S.; Nichols, K.E.; Cron, R.Q. The Immunology of Macrophage Activation Syndrome. *Front. Immunol.* 2019, 10, 119. [CrossRef]

2. Jin, P.; Wang, E. Polymorphism in clinical immunology–From HLA typing to immunogenetic profiling. *J. Transl. Med.* 2003, 1, 8. [CrossRef]

3. Howell, W.M.; Rose-Zerilli, M.J. Cytokine Gene Polymorphisms, Cancer Susceptibility, and Prognosis. *J. Nutr.* 2007, 137, 1945S–1995S. [CrossRef]

4. de Oliveira, J.G.; Rossi, A.F.T.; Nizato, D.M.; Cadamuro, A.C.T.; Jorge, Y.C.; Valsechi, M.C.; Silva, A.E. Influence of functional polymorphisms in TNF-α, IL-8, and IL-10 cytokine genes on mRNA expression levels and risk of gastric cancer. *Tumour Biol.* 2015, 36, 9195–9170. [CrossRef] [PubMed]

5. Hu, Y.; Wu, L.; Li, D.; Zhao, Q.; Jiang, W.; Xu, B. Association between cytokine gene polymorphisms and tuberculosis in a Chinese population: A case–control study. *BMC Immunol.* 2015, 16, 8. [CrossRef] [PubMed]

6. Bidwell, J.; Keen, L.; Gallagher, G.; Kimberly, R.; Huizinga, T.; McDermott, M.; Oksenberg, J.; McNicholl, J.; Pociot, F.; Hardt, C.; et al. Cytokine gene polymorphism in human disease: On-line databases. *Genes Immun.* 1999, 1, 3–19. [CrossRef]

7. Dinarello, C.A. Proinflammatory Cytokines. *Clin. Infect. Dis.* 2020, 71, 762–768. [CrossRef] [PubMed]

8. Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Tian, D.S. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. *Clin. Infect. Dis.* 2020, 71, 395–3934. [CrossRef] [PubMed]

9. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. *Lancet* 2020, 395, 1053–1034. [CrossRef] [PubMed]

10. Sorbera, L.A.; Graul, A.I.; Dulsat, C. Taking aim at a fast-moving target: Targets to watch for SARS-CoV-2 and COVID-19. *Drugs Future* 2020, 45, 1–6. [CrossRef]

11. Abdelwahab, S.F.; Zakaria, Z.; Sobby, M.; Hamdy, S.; Mahmoud, M.A.; Mikhail, N.; Allam, W.; Rewisha, E.; Waked, I. Differential distribution of IL28B rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response. *Arch. Virol.* 2015, 160, 1741–1750. [CrossRef]

12. Mehta, M.; Hetta, H.F.; Abdel-Hameed, E.A.; Rouster, S.D.; Hossain, M.; Mekky, M.A.; Khalil, N.K.; Mohamed, W.A.; El-Feky, M.A.; Ahmed, S.H.; et al. Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients. *Arch. Virol.* 2016, 161, 3161–3169. [CrossRef] [PubMed]

13. Wróblewska, A.; Bernat, A.; Woziwodzka, A.; Markiewicz, J.; Romanowski, T.; Bielawski, K.P.; Smiatecz, T.; Sikorska, K. Interferon lambda polymorphisms associate with body iron indices and hepatic expression of interferon-responsive long non-coding RNA in chronic hepatitis C. *Clin. Exp. Med.* 2016, 17, 225–232. [CrossRef] [PubMed]

14. Sheppard, M.; Webb, C.; Heath, F.; Mallows, V.; Emilianus, R.; Maskell, D.; Mastroeni, P. Dynamics of bacterial growth and distribution within the liver during Salmonella infection. *Cell Microbiol.* 2003, 5, 593–600. [CrossRef]

15. Deggren, C.; Gad, H.H.; Hamming, O.J.; Melchjorsen, J.; Hartmann, R. Human interferon-λ3 is a potent member of the type III interferon family. *Genes Immun.* 2008, 10, 125–131. [CrossRef] [PubMed]

16. John, M.; Metwally, M.; Mangia, A.; Romero-Gomez, M.; Berg, T.; Sheridan, D.; Eslam, M. TLL1 rs17047200 Increases the Risk of Treg in chronically HCV-infected patients. *Immunol. Investig.* 2020, 51, 208. [CrossRef] [PubMed]

17. Shrivastava, A.; Radziejewski, C.; Campbell, E.; Kovac, L.; McGlynn, M.; Ryan, T.E.; Davis, S.; Goldfarb, M.P.; Glass, D.J.; Lemke, G.; et al. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. *J. Cell Biol.* 2005, 120, 25–34. [CrossRef]

18. Yoshimura, T.; Kawano, Y.; Arimura, N.; Kawabata, S.; Kikuchi, A.; Kawabata, S.; Kikuchi, A.; Kaibuchi, K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. *Cell* 2003, 120, 137–149. [CrossRef]

19. Fukunaga-Kalabis, M.; Martinez, G.; Liu, Z.-J.; Kalabis, J.; Mraz, P.; Weninger, W.; Firth, S.M.; Plange, N.; Perbal, B.; Herlyn, M. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. *J. Cell Biol.* 2006, 175, 563–569. [CrossRef]

20. Masoud, H.H.; Ellassal, G.; Zaky, S.; Kamal, E.K. Management Protocol for COVID-19 Patients Version 1.4/30th May 2020 Ministry of Health and Population: Cairo, Egypt, 2020. Available online: http://www.mohp.gov.eg/JobsDetails.aspx?job_id=3061 (accessed on 27 May 2021).

21. Radwan, G.N. Epidemiology of SARS-CoV-2 in Egypt. *East Mediterr. Health J.* 2020, 26, 768–773. [CrossRef] [PubMed]

22. Saleh, A.; Sultan, A.; Elashry, M.A.; Farag, A.; Mortada, M.I.; Ghannam, M.A.; Saed, A.M.; Ghoneem, S. Association of TNF-α G-308A Promoter Polymorphism with the Course and Outcome of COVID-19 Patients. *Int. J. Mol. Sci.* 2020, 21, 3089. [CrossRef] [PubMed]

23. Ellinghaus, D.; Degenhardt, F.; Bujanda, L. 2020 Genomewide association study of severe Covid-19 with respiratory failure. *N. Engl. J. Med.* 2020, 383, 1522–1534. [CrossRef]

24. Hu, B.; Huang, S.; Yin, L. The cytokine storm and COVID-19. *J. Med. Virol.* 2021, 93, 250–256. [CrossRef] [PubMed]

25. Murray, M.F.; Kenny, E.E.; Ritchie, M.D. COVID-19 outcomes and the human genome. *Genet. Med.* 2020, 22, 1175–1177. [CrossRef]

26. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N. Engl. J. Med.* 2020, 382, 727–733. [CrossRef]
28. Mastroeni, P.; Sheppard, M. Salmonella infections in the mouse model: Host resistance factors and in vivo dynamics of bacterial spread and distribution in the tissues. *Microb Infect.* 2004, 6, 398–405. [CrossRef] [PubMed]

29. Lasfar, A.; Lewis-Antes, A.; Smirnov, S.V.; Anantha, S.; Abushahba, W.; Tian, B.; Reuhl, K.; Dickensheets, H.; Sheik, F.; Donnelly, R.P.; et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. *Cancer Res.* 2006, 66, 4468–4477. [CrossRef] [PubMed]

30. Balagopal, A.; Thomas, D.L.; Thio, C.L. IL28B and the Control of Hepatitis C Virus Infection. *Gastroenterology* 2010, 139, 1865–1876. [CrossRef] [PubMed]

31. Juárez-Vicuña, Y.; Pérez-Ramos, J.; Adalid-Peralta, L.; Sánchez, F.; Springall, R.; Villaseñor-Jasso, J.; Sixtos-Alonso, M.S.; Ballinas-Verdugo, M.A.; Márquez-Velasco, R.; Bojalil, R.; et al. The presence of IFI3/4 rs12979860 C allele influences the in vitro IP-10 production by mononuclear cells from patients with systemic lupus erythe-matosus. *Lupus* 2020, 29, 482–489. [CrossRef]

32. Matsuura, K.; Sawai, H.; Ikeo, K.; Ogawa, S.; Iio, E.; Isogawa, M.; Shimada, N.; Komori, A.; Toyoda, H.; Kumada, T.; et al. Genome-Wide Association Study Identifies TLL1 Variant Associated with Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. *Gastroenterology* 2017, 152, 1383–1394. [CrossRef] [PubMed]

33. De Castro, C.C.S.; Nascimento, L.M.D.; Walker, G.; Werneck, R.I.; Nogoceke, E.; Mira, M.T. Genetic Variants of the DDR1 Gene Are Associated with Vitiligo in Two Independent Brazilian Population Samples. *J. Investig. Dermatol.* 2010, 130, 1813–1818. [CrossRef] [PubMed]

34. Leitinger, B. Discoidin Domain Receptor Functions in Physiological and Pathological Conditions. *Int. Rev. Cell Mol. Biol.* 2014, 310, 39–87. [CrossRef]

35. Wang, L.; He, W.; Yu, X.; Hu, D.; Bao, M.; Liu, H.; Zhou, J.; Jiang, H. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. *J. Infect.* 2020, 80, 639–645. [CrossRef]

36. Li, M.; Yao, D.; Zeng, X.; Kasakovski, D.; Zhang, Y.; Chen, S.; Zha, X.; Li, Y.; Xu, L. Age related human T cell subset evolution and senescence. *Immun. Ageing* 2019, 16, 24. [CrossRef]

37. Weng, N.-P.; Akbar, A.N.; Goronzy, J. CD28–T cells: Their role in the age-associated decline of immune function. *Trends Immunol.* 2009, 30, 306–312. [CrossRef] [PubMed]

38. Wong, P.; Pamer, E.G. CD8 T cell responses to infectious pathogens. *Annu. Rev. Immunol.* 2003, 21, 29–70. [CrossRef] [PubMed]